regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-20. Anything still debated is marked as such rather than presented as settled.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
=== Tenerife === Upon landing on Tenerife, Humboldt and Bonpland were received by local officials and noted the distinctive flora of the island, including bananas, papaws, and ornamental plants. On June 20, before dawn,Bonpland an Humboldt departed with guides and mules for La Orotava, near the Teide volcano. They passed through San Cristébal, built on a basalt ridge around the Peak of Tenerife, and paused to inspect rocks, eventually arriving at La Laguna, the capital of Tenerife. After the climbing Humboldt and his party left La Laguna, traversing a landscape rich in plant diversity, including palms, orange trees, vines, and cacti. The region’s natural beauty was contrasted by socio-economic inequality, with land concentrated among a few wealthy planters and the indigenous population living in poverty. The group passed through Juan de la Rambla, Victoria, and Matanza, sites of both agricultural abundance and historical conflict with Spanish conquest in the fifteenth century. In La Orotava, they visited the botanical garden and met Monsieur LeGros, the French vice-consul, who had lived on Tenerife since being shipwrecked and agreed to guide their ascent of Pico del Teide. On 21 June 1799, the climbing party, which included LeGros, other local guides, and consular staff, departed for the volcano. The route passed solidly built but somber towns, lush gardens, and a renowned dragon tree, a species present in the Canaries but native to the West Indies, illustrating the complexities of plant distribution.
==== Interactions with B cells ==== Macrophages have been shown to secrete cytokines BAFF and APRIL, which are important for plasma cell isotype switching. APRIL and IL-6 secreted by macrophage precursors in the bone marrow help maintain survival of plasma cells homed to the bone marrow.
Specific gravity—(using a hydrometer test strip or some sort of floating indicator), Refractometer—which measures the refractive index of the antifreeze solution, and Test strips—specialized, disposable indicators made for this purpose. Both specific gravity and refractive index are affected by temperature, although the former is affected much less catastrophically. Temperature compensation is nevertheless recommended for RI measurement. Propylene glycol solutions cannot be tested using specific gravity because of ambiguous results (40% and 100% solutions have the same specific gravity), although typical uses rarely exceed 60% concentration. The boiling point can be similarly determined by a concentration given from one of the three methods. Datasheets for glycol/water coolant mixtures are commonly available from chemical vendors.
Marcus (1948), cardiologist and professor at University of Arizona Medical Center Frederick Reif (1948), professor of physics and psychology at Carnegie Mellon University, recipient of the 1994 Robert A. Millikan Award Robert Neil Butler (1949), president of the International Longevity Center and winner of the Pulitzer Prize for General Nonfiction William Chinowsky (1949), astrophysicist and professor at the University of California, San Diego Edgar Housepian (1949), neurosurgeon, co-founder of the Fund for Armenian Relief Benjamin Widom (1949), professor of chemistry at Cornell University; recipient of the Boltzmann Medal in 1998 Noel Corngold (1950), physicist at California Institute of Technology Edwin Kessler (1950), first director of the National Severe Storms Laboratory Gerald Weissmann (1950), cell biologist, liposome inventor, essayist Arthur H. Westing (1950), ecologist and researcher at Stockholm International Peace Research Institute Leon Cooper (1951), winner of the Nobel Prize in Physics in 1972 Richard A. Gardner (1952), psychiatrist known for researching Parental alienation syndrome Edgar Haber (1952), former president of Bristol-Myers Squibb and professor at Harvard Medical School Donald E.
Excess matrix metalloproteinases, which are released by leukocytes, may also cause wounds to become chronic. MMPs break down ECM molecules, growth factors, and protease inhibitors, and thus increase degradation while reducing construction, throwing the delicate compromise between production and degradation out of balance.
Sources: en.wikipedia.org
=== Regulatory status === This medication first reached market in 1973. It is approved in 21 countries worldwide, which does not include its home country of Denmark. It was taken off the approved list in India in 2014, citing a lack of required information such as mandatory clinical trial results in its 1998 approval decision. It is approved in China.
=== July === 1 July – Dennis Lattimer, muralist (born 1946). 2 July – Des Gorman, diving and hyperbaric medicine specialist (University of Auckland) and health bureaucrat (born 1953). 3 July Terry Brown, brothel owner (born 1956/1957). (death announced on this date) Hilary Stace, disability and autism advocate, eugenics researcher (born 1954) 5 July – Tim Bray, actor, comedian, and children's theatre founder (born 1964). 6 July – Kay Bradford, child and adolescent psychiatrist (born 1930). 9 July – Bruce Harris, legal academic (University of Otago, University of Auckland). 11 July Bert Brownlie, economist (University of Auckland, University of Canterbury) and university administrator, University of Canterbury vice-chancellor (1977–1998) (born 1932). Alex McNabb, mathematician (DSIR), Fellow of the Royal Society of New Zealand (since 1985) (born 1930). 12 July – Heather Roe, field hockey player (national team) (born 1939). 15 July – Neill Price, firefighter, local politician and community leader, Waimakariri District Councillor (1989–1998) (born 1936). 16 July Chris Faiumu, musician (Fat Freddy's Drop) and reggae-dub producer. Bruce McTavish, boxing referee (born 1940). Andrew Oliver, oldest person known to have survived with Fryns–Aftimos syndrome (born c. 1984). 17 July Barrie Downey, business executive (Fletcher Challenge) (born 1930). Don McIntosh, rugby union player (Wellington, national team) (born 1931). Greer Twiss, sculptor (Karangahape Rocks) and educator (University of Auckland), Arts Foundation of New Zealand Icon (since 2011) (born 1937).
=== Anion exchange === Anion exchange sorbents are derivatized with positively charged functional groups that interact and retain negatively charged anions, such as acids. Strong anion exchange sorbents contain quaternary ammonium groups that have a permanent positive charge in aqueous solutions, and weak anion exchange sorbents use amine groups which are charged when the pH is below about 9. Strong anion exchange sorbents are useful because any strongly acidic impurities in the sample will bind to the sorbent and usually will not be eluted with the analyte of interest; to recover a strong acid a weak anion exchange cartridge should be used. To elute the analyte from either the strong or weak sorbent, the stationary phase is washed with a solvent that neutralizes the charge of either the analyte, the stationary phase, or both. Once the charge is neutralized, the electrostatic interaction between the analyte and the stationary phase no longer exists and the analyte will elute from the cartridge.
It has been particularly successful at analyzing "decoy" structures from ab initio structure prediction. These decoys are notorious for getting local fragment motif structure correct, and forming some kernels of correct 3D tertiary structure but getting the full length tertiary structure wrong. In this twilight remote homology regime, Mammoth's e-values for the CASP protein structure prediction evaluation have been shown to be significantly more correlated with human ranking than SSAP or DALI. Mammoths ability to extract the multi-criteria partial overlaps with proteins of known structure and rank these with proper E-values, combined with its speed facilitates scanning vast numbers of decoy models against the PDB data base for identifying the most likely correct decoys based on their remote homology to known proteins.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.